Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Public ClinicalTrials.gov record NCT01110499. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study has 2 parts. Part 1 will evaluate the safety and IOP effects of 6 formulations of AGN-210961 ophthalmic solution in the study eye and bimatoprost ophthalmic solution 0.03% in the fellow eye for 7 consecutive days. Part 2 will evaluate the safety and IOP effects of a formulation (to be selected from part 1) of AGN-210961 in both eyes compared to bimatoprost ophthalmic solution 0.03% for 4 weeks.
Study identification
- NCT ID
- NCT01110499
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 163 participants
Conditions and interventions
Conditions
Interventions
- AGN-210961 Formulation 1 Drug
- AGN-210961 Formulation 2 Drug
- AGN-210961 Formulation 3 Drug
- AGN-210961 Formulation 4 Drug
- AGN-210961 Formulation 5 Drug
- AGN-210961 Formulation 6 Drug
- AGN-210961 Formulation 7 Drug
- bimatoprost ophthalmic solution 0.03% Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2010
- Primary completion
- Apr 30, 2011
- Completion
- May 31, 2011
- Last update posted
- Aug 4, 2014
2010 – 2011
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Newport Beach | California | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Ocular Hypertension trials
Other public records listing Ocular Hypertension. Sorted by last update posted; newest first. Not a recommendation.
- NCT04401982: Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects Recruiting
- NCT07588152: Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension Not yet recruiting
- NCT07325240: 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients Recruiting
- NCT07390890: DSLT for Reducing Medication in Glaucoma Recruiting
- NCT04499248: AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension Recruiting
- NCT07217678: Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01110499, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 4, 2014 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01110499 live on ClinicalTrials.gov.